CNS Brain Metastases, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Conditions
Brief summary
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Interventions
PROCEDUREPET-imaging with CuATSM
imaging with CuATSM
PROCEDUREPET Imaging
Imaging with CuATSM
PROCEDUREPET CuATSM
Imaging with CuATSM
PROCEDUREPET imaging
imaging with CuATSM
PROCEDUREPET imaging with CuATSM
Imaging with CuATSM
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Able to tolerated a PET/CT scan * Age 18 or older * Patient being considered for XRT for treatment of their cancer * Able to provide written informed consent
Exclusion criteria
* severe claustrophobia or inability to tolerate the PET scan * pregnant or breastfeeding women * Patients that need supplemental oxygen * Patients enrolled in experimental treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia | end of study |
Secondary
| Measure | Time frame |
|---|---|
| To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans | end of study |
| To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients | end of study |
Countries
United States
Outcome results
None listed